$7M for Satori Pharmaceuticals
Satori Pharmaceuticals, a Cambridge, MA-based developer of treatments for Alzheimer’s disease, has raised $7 million in equity funding, according to an SEC filing. The funding is part of Satori’s previously disclosed $22 million round of financing, according to an e-mail from company director Daphne Zohar, a managing partner at PureTech Ventures in Boston. Satori’s investors include PureTech, InterWest Partners, New Enterprise Associates, Prospect Venture Partners, and others. Zohar, whose firm formed Satori in 2005, was also the startup’s founding CEO, according to Satori’s website.